The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Polymyxin B Sulfate and Colistin: Old Antibiotics for Emerging Multiresistant Gram-Negative Bacteria
Abstract
BACKGROUND: Polymyxin B sulfate and colistin, also known as colistimethate, have not been used for many years because less toxic antimicrobials are available. Gram-negative bacteria that are resistant to the aminoglycosides, β-lactams, and fluoroquinolones are becoming more common. These bacteria are often susceptible to the polymyxins. OBJECTIVE: To present a review of the chemistry, antibacterial spectrum, dosing, pharmacokinetics, toxicity, and indications for polymyxin B sulfate and colistin. DATA SOURCE: A MEDLINE search (1966–1998) of the English-language literature was performed to identify primary literature on the polymyxins. Older citations (1949–1965) were identified through the bibliographies of these articles. STUDY SELECTION: All available reports of in vitro antibacterial activity, animal and clinical trials, and case reports were reviewed. DATA SYNTHESIS: The polymyxins are amphipathic molecules that interact with lipopolysaccharide in the bacterial outer membrane. They have potent antiendotoxic properties and antibacterial activity against Pseudomonas aeruginosa and many of the Enterobacteriaceae. Polymyxin B and colistin are usually given at a dose of 1.5–2.5 and 5 mg/kg/d, respectively, in two divided doses. Dosing must be altered in renal failure since the kidney is the primary route of elimination. Distribution into pleural fluid, joints, and cerebrospinal fluid is poor. Toxic effects involve the kidney and central nervous system. The polymyxins are recommended for serious systemic infections caused by gram-negative bacteria that are resistant to other agents. CONCLUSIONS: Polymyxin B sulfate and colistin have a role in the therapy of multidrug-resistant gram-negative bacterial infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Binding of polymyxin B to the lipid A portion of bacterial lipopolysaccharides
Morrison, D. C., & Jacobs, D. M. (1976) · Immunochemistry · doi:10.1016/0019-2791(76)90181-6 · Cited by 819
Polymyxin and Related Peptide Antibiotics
Storm, D. R., Rosenthal, K. S., & Swanson, P. E. (1977) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.46.070177.003451 · Cited by 759
THE BARRIER FUNCTION OF THE GRAM‐NEGATIVE ENVELOPE
Leive, L. (1974) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1974.tb43261.x · Cited by 510
Archibald, L., Phillips, L., Monnet, D., McGowan, J. E., Tenover, F., & Gaynes, R. (1997) · Clinical Infectious Diseases · doi:10.1093/clinids/24.2.211 · Cited by 436
Interaction of divalent cations and polymyxin B with lipopolysaccharide
Schindler, M., & Osborn, M. J. (1979) · Biochemistry · doi:10.1021/bi00587a024 · Cited by 334
Compounds which increase the permeability of the Pseudomonas aeruginosa outer membrane
Hancock, R. E., & Wong, P. G. (1984) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.26.1.48 · Cited by 282
Aerosol Polymyxin and Pneumonia in Seriously Ill Patients
Feeley, T. W., du Moulin, G. C., Hedley-Whyte, J., Bushnell, L. S., Gilbert, J. P., & Feingold, D. S. (1975) · New England Journal of Medicine · doi:10.1056/nejm197509042931003 · Cited by 261
Nicas, T. I., & Hancock, R. E. W. (1980) · Journal of Bacteriology · doi:10.1128/jb.143.2.872-878.1980 · Cited by 221
Vaara, M., Vaara, T., Jensen, M., Helander, I., Nurminen, M., Rietschel, E. T., & Mäkelä, P. H. (1981) · FEBS Letters · doi:10.1016/0014-5793(81)80777-6 · Cited by 195
Electron microscopic studies on mode of action of polymyxin
Koike, M., Iida, K., & Matsuo, T. (1969) · Journal of Bacteriology · doi:10.1128/jb.97.1.448-452.1969 · Cited by 172
Tauber, M. G., Shibl, A. M., Hackbarth, C. J., Larrick, J. W., & Sande, M. A. (1987) · Journal of Infectious Diseases · doi:10.1093/infdis/156.3.456 · Cited by 165
Reetze-Bonorden, P., Böhler, J., & Keller, E. (1993) · Clinical Pharmacokinetics · doi:10.2165/00003088-199324050-00002 · Cited by 158
Binding of polycationic antibiotics and polyamines to lipopolysaccharides of Pseudomonas aeruginosa
Peterson, A. A., Hancock, R. E. W., & McGroarty, E. J. (1985) · Journal of Bacteriology · doi:10.1128/jb.164.3.1256-1261.1985 · Cited by 156
Jacobs, D. M., & Morrison, D. C. (1977) · The Journal of Immunology · doi:10.4049/jimmunol.118.1.21 · Cited by 142
Susceptibility of gram-negative bacteria to polymyxin B nonapeptide
Viljanen, P., & Vaara, M. (1984) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.25.6.701 · Cited by 112
Cavaillon, J., & Haeffner‐Cavaillon, N. (1986) · Molecular Immunology · doi:10.1016/0161-5890(86)90127-6 · Cited by 105
Interferon-gamma induction by lipopolysaccharide: dependence on interleukin 2 and macrophages.
Blanchard, D. K., Djeu, J. Y., Klein, T., Friedman, H. P., & Stewart, W. E. (1986) · The Journal of Immunology · doi:10.4049/jimmunol.136.3.963 · Cited by 101
Nord, N. M., & Hoeprich, P. D. (1964) · New England Journal of Medicine · doi:10.1056/nejm196405142702002 · Cited by 97
Electron Microscopy of Effect of Polymyxin on Escherichia coli Lipopolysaccharide
Lopes, J., & Inniss, W. E. (1969) · Journal of Bacteriology · doi:10.1128/jb.100.2.1128-1130.1969 · Cited by 90
Wispelwey, B., Hansen, E. J., & Scheld, W. M. (1989) · Infection and Immunity · doi:10.1128/iai.57.8.2559-2562.1989 · Cited by 83
Stokes, D. C., Shenep, J. L., Fishman, M., Hildner, W. K., Bysani, G. K., & Rufus, K. (1989) · The Journal of Infectious Diseases · doi:10.1093/infdis/160.1.52 · Cited by 82
Inhibition of lipopolysaccharide-initiated activation of serum complement by polymyxin B
Morrison, D. C., & Jacobs, D. M. (1976) · Infection and Immunity · doi:10.1128/iai.13.1.298-301.1976 · Cited by 81
Decreased binding of polymyxin by polymyxin-resistant mutants of Salmonella typhimurium
Vaara, M., Vaara, T., & Sarvas, M. (1979) · Journal of Bacteriology · doi:10.1128/jb.139.2.664-667.1979 · Cited by 78
LaPorte, D. C., Rosenthal, K. S., & Storm, D. R. (1977) · Biochemistry · doi:10.1021/bi00627a019 · Cited by 76
Endotoxin-induced intravascular coagulation: prevention with polymyxin B sulfate.
Jj, C., & Bm, B. (1971) · PubMed · Cited by 74
Hoeprich, P. D. (1970) · Medical Clinics of North America · doi:10.1016/s0025-7125(16)32591-3 · Cited by 69
Effect of Polymyxin B Sulfate on Endotoxin Activity in a Gram-Negative Septicemia Model
Corrigan, J. J., & Kiernat, J. F. (1979) · Pediatric Research · doi:10.1203/00006450-197901000-00011 · Cited by 68
Bader, J., & Teuber, M. (1973) · PubMed · Cited by 62
Conrad, R. S., & Galanos, C. (1989) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.33.10.1724 · Cited by 59
Effect of Polymyxin B on Experimental Shock from Meningococcal and Escherichia coli Endotoxins
Baldwin, G., Alpert, G., Caputo, G. L., Baskin, M., Parsonnet, J., Gillis, Z. A., Thompson, C. C., Siber, G. R., & FLEISHER, G. R. (1991) · The Journal of Infectious Diseases · doi:10.1093/infdis/164.3.542 · Cited by 56
[Amino acid metabolism in larvae of the silkworm Bombyx mori].
Filippovich, I. B., & Bungova, V. G. (1968) · PubMed · Cited by 54
Isolation and genetic characterization of polymyxin-resistant mutants of Salmonella
Mäkelä, P. H., Sarvas, M., Calcagno, S., et al. (1978) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.1978.tb01963.x · Cited by 51
Polymyxin B Moderates Acidosis and Hypotension in Established, Experimental Gram-Negative Septicemia
Flynn, P. M., Shenep, J. L., Stokes, D. C., Fairclough, D. L., & Hildner, W. K. (1987) · The Journal of Infectious Diseases · doi:10.1093/infdis/156.5.706 · Cited by 48
Polymyxin B and polymyxin E; clinical and laboratory studies.
Kagan, B. M., KREVSKY, D. A., MILZER, A., & Locke, M. (1951) · PubMed · Cited by 44
Disruption of Escherichia coli outer membranes by EM 49. A new membrane active peptide antibiotic
Rosenthal, K. S., Swanson, P. E., & Storm, D. R. (1976) · Biochemistry · doi:10.1021/bi00671a015 · Cited by 41
Emergence of bacterial resistance to imipenem and ciprofloxacin in a university hospital
Fass, R. J., Barnishan, J., & Ayers, L. W. (1995) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/36.2.343 · Cited by 40
EM49: A NEW POLYPEPTIDE ANTIBIOTIC ACTIVE AGAINST CELL MEMBRANES
Meyers, E., Parker, W. L., Brown, W. E., Linnett, P. E., & Strominger, J. L. (1974) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1974.tb43286.x · Cited by 37
Armstrong, D., Neu, H. C., Peterson, L. R., et al. (1995) · Microbial Drug Resistance · doi:10.1089/mdr.1995.1.1 · Cited by 33
Lethal Effect of Complement and Lysozyme on Polymyxin-Treated, Serum-Resistant Gram-Negative Bacilli
Fierer, J., & Finley, F. (1979) · The Journal of Infectious Diseases · doi:10.1093/infdis/140.4.581 · Cited by 28
Bader, J., & Teuber, M. (1973) · Zeitschrift für Naturforschung C · doi:10.1515/znc-1973-7-811 · Cited by 24
Lasfargues, A., Tahri-Jouti, M.-A., Pédron, T., Girard, R., & Chaby, R. (1989) · European Journal of Immunology · doi:10.1002/eji.1830191207 · Cited by 23
Butler, T., & Möller, G. (1977) · Infection and Immunity · doi:10.1128/iai.18.2.400-404.1977 · Cited by 13
TETRACYCLINE-SENSITIVE/POLYMYXIN-RESISTANT PSEUDOMONAS ÆRUGINOSA
Brown, M. R., Fenton, E. M., & Watkins, W. M. (1972) · The Lancet · doi:10.1016/s0140-6736(72)91568-1 · Cited by 8
Cited by
Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections
Li, J., Nation, R. L., Turnidge, J. D., Milne, R. W., Coulthard, K., Rayner, C. R., & Paterson, D. L. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70580-1 · Cited by 1,388
Antibacterial peptides for therapeutic use: obstacles and realistic outlook
MARR, A., GOODERHAM, W., & HANCOCK, R. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.04.006 · Cited by 1,051
Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review
Zavascki, A. P., Goldani, L. Z., Li, J., & Nation, R. L. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm357 · Cited by 834
Moffatt, J. H., Harper, M., Harrison, P., Hale, J. D. F., Vinogradov, E., Seemann, T., Henry, R., Crane, B., St. Michael, F., Cox, A. D., et al. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00834-10 · Cited by 812
Ciprofloxacin Causes Persister Formation by Inducing the TisB toxin in Escherichia coli
Dörr, T., Vulić, M., & Lewis, K. (2010) · PLoS Biology · doi:10.1371/journal.pbio.1000317 · Cited by 782
Metadata
- Authors
- Evans, M. E., Feola, D. J., & Rapp, R. P.
- Venue
- Annals of Pharmacotherapy
- Publisher
- SAGE Publications
- Published
- 1999-09
- Volume
- 33
- Issue
- 9
- Pages
- 960-967
- ISSN
- 0012-6578 (ISSN-L)
- 1060-0280
- 1542-6270
- OpenAlex
- W2162745520
- Cited by
- 544
- References
- 43
- FWCI
- 4.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.